Annual CFF
-$25.21 M
-$39.80 M-272.67%
31 December 2023
Summary:
Akebia Therapeutics annual cash flow from financing activities is currently -$25.21 million, with the most recent change of -$39.80 million (-272.67%) on 31 December 2023. During the last 3 years, it has fallen by -$256.93 million (-110.88%). AKBA annual CFF is now -110.88% below its all-time high of $231.72 million, reached on 31 December 2020.AKBA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$1.22 M
-$6.42 M-83.99%
30 September 2024
Summary:
Akebia Therapeutics quarterly cash flow from financing activities is currently $1.22 million, with the most recent change of -$6.42 million (-83.99%) on 30 September 2024. Over the past year, it has increased by +$1.17 million (+2346.00%). AKBA quarterly CFF is now -99.14% below its all-time high of $142.81 million, reached on 30 June 2020.AKBA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$26.05 M
+$1.17 M+4.72%
30 September 2024
Summary:
Akebia Therapeutics TTM cash flow from financing activities is currently $26.05 million, with the most recent change of +$1.17 million (+4.72%) on 30 September 2024. Over the past year, it has increased by +$49.97 million (+208.91%). AKBA TTM CFF is now -91.19% below its all-time high of $295.63 million, reached on 30 September 2020.AKBA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AKBA Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -272.7% | +2346.0% | +208.9% |
| 3 y3 years | -110.9% | -92.6% | -83.6% |
| 5 y5 years | -126.1% | +527.2% | +585.7% |
AKBA Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -110.9% | at low | -97.4% | +103.7% | -83.6% | +145.8% |
| 5 y | 5 years | -110.9% | at low | -99.1% | +103.7% | -91.2% | +145.8% |
| alltime | all time | -110.9% | at low | -99.1% | +103.7% | -91.2% | +145.8% |
Akebia Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.22 M(-84.0%) | $26.05 M(+4.7%) |
| June 2024 | - | $7.64 M(-58.6%) | $24.88 M(+169.4%) |
| Mar 2024 | - | $18.48 M(-1532.2%) | $9.23 M(-136.6%) |
| Dec 2023 | -$25.21 M(-272.7%) | -$1.29 M(-2680.0%) | -$25.21 M(+5.4%) |
| Sept 2023 | - | $50.00 K(-100.6%) | -$23.92 M(-58.0%) |
| June 2023 | - | -$8.00 M(-49.9%) | -$56.90 M(+16.3%) |
| Mar 2023 | - | -$15.97 M(>+9900.0%) | -$48.91 M(-435.1%) |
| Dec 2022 | $14.60 M(-89.1%) | -$1000.00(-100.0%) | $14.60 M(-27.0%) |
| Sept 2022 | - | -$32.94 M(>+9900.0%) | $20.00 M(-71.2%) |
| June 2022 | - | -$9000.00(-100.0%) | $69.42 M(-35.0%) |
| Mar 2022 | - | $47.55 M(+780.0%) | $106.80 M(-20.1%) |
| Dec 2021 | $133.73 M(-42.3%) | $5.40 M(-67.2%) | $133.73 M(-15.8%) |
| Sept 2021 | - | $16.48 M(-55.9%) | $158.84 M(+10.8%) |
| June 2021 | - | $37.37 M(-49.8%) | $143.41 M(-42.4%) |
| Mar 2021 | - | $74.48 M(+144.1%) | $248.85 M(+7.4%) |
| Dec 2020 | $231.72 M(+160.4%) | $30.51 M(+2794.8%) | $231.72 M(-21.6%) |
| Sept 2020 | - | $1.05 M(-99.3%) | $295.63 M(+0.3%) |
| June 2020 | - | $142.81 M(+149.0%) | $294.77 M(+83.4%) |
| Mar 2020 | - | $57.35 M(-39.3%) | $160.76 M(+80.7%) |
| Dec 2019 | $88.97 M(-7.9%) | $94.42 M(>+9900.0%) | $88.97 M(-1759.0%) |
| Sept 2019 | - | $195.00 K(-97.8%) | -$5.36 M(+3.1%) |
| June 2019 | - | $8.80 M(-160.9%) | -$5.20 M(-62.3%) |
| Mar 2019 | - | -$14.45 M(<-9900.0%) | -$13.80 M(-114.3%) |
| Dec 2018 | $96.56 M | $85.00 K(-76.0%) | $96.56 M(-5.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | $354.00 K(+67.0%) | $101.72 M(-38.4%) |
| June 2018 | - | $212.00 K(-99.8%) | $165.15 M(-21.5%) |
| Mar 2018 | - | $95.91 M(+1729.3%) | $210.41 M(+81.0%) |
| Dec 2017 | $116.24 M(+73.6%) | $5.24 M(-91.8%) | $116.24 M(+1.5%) |
| Sept 2017 | - | $63.78 M(+40.3%) | $114.53 M(+115.8%) |
| June 2017 | - | $45.47 M(+2504.0%) | $53.07 M(+606.7%) |
| Mar 2017 | - | $1.75 M(-50.5%) | $7.51 M(-88.8%) |
| Dec 2016 | $66.95 M(-19.4%) | $3.53 M(+51.5%) | $66.95 M(-1.2%) |
| Sept 2016 | - | $2.33 M(-2577.7%) | $67.76 M(-14.6%) |
| June 2016 | - | -$94.00 K(-100.2%) | $79.38 M(-45.0%) |
| Mar 2016 | - | $61.18 M(+1309.7%) | $144.23 M(+73.6%) |
| Dec 2015 | $83.09 M(-20.4%) | $4.34 M(-68.9%) | $83.09 M(+5.6%) |
| Sept 2015 | - | $13.95 M(-78.5%) | $78.70 M(+21.8%) |
| June 2015 | - | $64.75 M(>+9900.0%) | $64.63 M(-5052.5%) |
| Mar 2015 | - | $49.00 K(-202.1%) | -$1.30 M(-101.3%) |
| Dec 2014 | $104.40 M(+146.6%) | -$48.00 K(-61.6%) | $104.40 M(+0.2%) |
| Sept 2014 | - | -$125.00 K(-89.4%) | $104.23 M(-0.1%) |
| June 2014 | - | -$1.18 M(-101.1%) | $104.32 M(-28.4%) |
| Mar 2014 | - | $105.75 M(<-9900.0%) | $145.60 M(+244.0%) |
| Dec 2013 | $42.33 M(+1610.3%) | -$215.00 K(+427.0%) | $42.33 M(-0.5%) |
| Sept 2013 | - | -$40.80 K(-100.1%) | $42.55 M(-0.1%) |
| June 2013 | - | $40.10 M(+1515.3%) | $42.59 M(+1615.3%) |
| Mar 2013 | - | $2.48 M | $2.48 M |
| Dec 2012 | $2.48 M | - | - |
FAQ
- What is Akebia Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Akebia Therapeutics?
- What is Akebia Therapeutics annual CFF year-on-year change?
- What is Akebia Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Akebia Therapeutics?
- What is Akebia Therapeutics quarterly CFF year-on-year change?
- What is Akebia Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Akebia Therapeutics?
- What is Akebia Therapeutics TTM CFF year-on-year change?
What is Akebia Therapeutics annual cash flow from financing activities?
The current annual CFF of AKBA is -$25.21 M
What is the all time high annual CFF for Akebia Therapeutics?
Akebia Therapeutics all-time high annual cash flow from financing activities is $231.72 M
What is Akebia Therapeutics annual CFF year-on-year change?
Over the past year, AKBA annual cash flow from financing activities has changed by -$39.80 M (-272.67%)
What is Akebia Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of AKBA is $1.22 M
What is the all time high quarterly CFF for Akebia Therapeutics?
Akebia Therapeutics all-time high quarterly cash flow from financing activities is $142.81 M
What is Akebia Therapeutics quarterly CFF year-on-year change?
Over the past year, AKBA quarterly cash flow from financing activities has changed by +$1.17 M (+2346.00%)
What is Akebia Therapeutics TTM cash flow from financing activities?
The current TTM CFF of AKBA is $26.05 M
What is the all time high TTM CFF for Akebia Therapeutics?
Akebia Therapeutics all-time high TTM cash flow from financing activities is $295.63 M
What is Akebia Therapeutics TTM CFF year-on-year change?
Over the past year, AKBA TTM cash flow from financing activities has changed by +$49.97 M (+208.91%)